We are testing a new medication, IDP-121, for patients with relapsed or refractory blood cancers like multiple myeloma and B-cell lymphoma. The goal is to find the best dose and see how well it helps improve patient outcomes.
Health conditions and diseases that the clinical trial is designed to study and treat.
Chronic Lymphocytic Leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the overproduction of abnormal lymphocytes, which can cause symptoms like fatigue, swollen lymph nodes, and frequent infections.
B-cell lymphomas are a group of blood cancers that originate from B-cells, a type of white blood cell, and can cause symptoms such as swollen lymph nodes, fever, and unexplained weight loss.
Multiple Myeloma (MM) is a cancer of plasma cells in the bone marrow, leading to the production of abnormal proteins that can cause symptoms like bone pain, fatigue, and kidney problems.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.